Showing results (1591-1600 of 1,659) with videos related to

Sort By:
Pageof 166
Transplantation and Cellular Therapy|September 19, 2025
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy ConsortiumKaren Sweiss, Charlotte Wagner, Eric Anto, et al.
Haematologica|October 19, 2023
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experienceHamza Hashmi, Doris K Hansen, Lauren C Peres, et al.
Bioorganic & Medicinal Chemistry Letters|April 5, 2011
Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discoveryDaniel A Erlanson, Joseph W Arndt, Mark T Cancilla, et al.
Open Forum Infectious Diseases|October 16, 2024
Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B ReactivationGuy Handley, Amanda Yepes, Eva Eliassen, et al.
Journal of Hematology & Oncology|June 6, 2024
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucelSaurabh Zanwar, Surbhi Sidana, Leyla Shune, et al.
Blood|April 8, 2025
Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR AnalysisSurbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, et al.
Brain : a Journal of Neurology|April 19, 2007
Large-scale pathways-based association study in amyotrophic lateral sclerosisDalia Kasperaviciute, Mike E Weale, Kevin V Shianna, et al.
ACS Medicinal Chemistry Letters|September 19, 2019
Discovery of <i>N</i>-(1-Acryloylazetidin-3-yl)-2-(1<i>H</i>-indol-1-yl)acetamides as Covalent Inhibitors of KRAS<sup>G12C</sup>Youngsook Shin, Joon Won Jeong, Ryan P Wurz, et al.
Blood Cancer Journal|March 21, 2026
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortiumCindy Varga, Myra Robinson, James A Davis, et al.
International Journal of Molecular Sciences|April 14, 2026
Polyfunctionalized <i>N</i>-Arylsulfonyl Indoles: Identification of (<i>E</i>)-<i>N</i>-Hydroxy-3-{3-[(5-(3-(piperidin-1-yl)propoxy]-1<i>H</i>-indol-1-yl)sulfonyl]phenyl}acrylamide (MTP150) for the Epigenetic-Based Therapy of Parkinson's DiseaseMireia Toledano-Pinedo, Alicia Porro-Pérez, Linda Schäker-Hübner, et al.
Pageof 166